| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Fund XII, L.P. By: ARCH Venture Partners XII, L.P., its General Partner By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0001979548 |
| ARCH Venture Fund XII, L.P. | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Partners XII, L.P. By: ARCH Venture Partners XII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0001906837 |
| ARCH Venture Partners XII, L.P. | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Partners XII, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0001979765 |
| ARCH Venture Fund XIII, L.P. | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Fund XIII, L.P. By: ARCH Venture Partners XIII, L.P., its General Partner By: ARCH Venture Partners XIII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0002006772 |
| ARCH Venture Partners XIII, L.P. | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Partners XIII, L.P. By: ARCH Venture Partners XIII, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0002016083 |
| ARCH Venture Partners XIII, LLC | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | ARCH Venture Partners XIII, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact | 14 Nov 2025 | 0002016082 |
| CRANDELL KEITH | Director, 10%+ Owner | C/O ARCH VENTURE PARTNERS IX, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | /s/ Keith Crandell, By: Mark McDonnell, attorney-in-fact | 14 Nov 2025 | 0001219039 |
| GILLIS STEVEN | Director, 10%+ Owner | C/O ARCH VENTURE PARTNERS, 8755 WEST HIGGINS ROAD, SUITE 1025, CHICAGO | /s/ Steven Gillis, By: Mark McDonnell, attorney-in-fact | 14 Nov 2025 | 0001229592 |
| NELSEN ROBERT | Director, 10%+ Owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO | /s/ Robert Nelsen, By: Mark McDonnell, attorney-in-fact | 14 Nov 2025 | 0001219042 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MTSR | Common Stock | Disposed to Issuer | -18,503,128 | -100% | 0 | 13 Nov 2025 | See Footnote | F1, F2, F3 | ||
| transaction | MTSR | Common Stock | Disposed to Issuer | -8,313,680 | -100% | 0 | 13 Nov 2025 | See Footnote | F1, F2, F4 |
ARCH Venture Partners XII, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus |
| F2 | (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). |
| F3 | Represents shares held directly by ARCH Venture Fund XII, L.P ("ARCH Venture Fund XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP"), as the sole general partner of ARCH Venture Fund XII, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. ARCH Venture Partners XII, LLC ("AVP XII LLC"), as the sole general partner of AVP XII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XII. AVP XII LP and AVP XII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XII LLC, each of Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (the "AVP XII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XII shares. Each AVP XII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |
| F4 | Represents shares held directly by ARCH Venture Fund XIII, L.P. ("ARCH Venture Fund XIII"). ARCH Venture Partners XIII, L.P. ("AVP XIII LP"), as the sole general partner of ARCH Venture Fund XIII, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. ARCH Venture Partners XIII, LLC ("AVP XIII LLC"), as the sole general partner of AVP XIII LP, may be deemed to beneficially own the shares held by ARCH Venture Fund XIII. AVP XIII LP and AVP XIII LLC disclaim beneficial ownership except to the extent of any pecuniary interest therein. As members of the investment committee of AVP XIII LLC, each of Paul L. Berns, Kristina M. Burow, Keith Crandell and Robert Nelsen (the "AVP XIII Committee Members") may also be deemed to share the power to direct the disposition and vote of the ARCH Venture Fund XIII shares. Each AVP XIII Committee Member disclaims beneficial ownership except to the extent of any pecuniary interest therein. |